Holen Sie sich die Stockscreener-App
3.64
2.15%
-0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.72
Offen:
$3.69
24-Stunden-Volumen:
1.61M
Relative Volume:
0.65
Marktkapitalisierung:
$325.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.17M
KGV:
-6.386
EPS:
-0.57
Netto-Cashflow:
$-37.10M
1W Leistung:
-0.82%
1M Leistung:
-5.70%
6M Leistung:
-61.96%
1J Leistung:
-71.02%
1-Tages-Spanne:
$3.57
$3.74
1-Wochen-Bereich:
$3.56
$3.82
52-Wochen-Spanne:
$2.86
$14.25
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corporation
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Vergleichen Sie AVXL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
3.64 | 332.37M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-09-23 | Eingeleitet | BTIG Research | Buy |
| 2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Eingeleitet | Janney | Buy |
| 2018-05-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-02-07 | Eingeleitet | Noble Financial | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Will Anavex Life Sciences Corp. stock continue upward momentumStock Screening Results & Free Smart Trading Classes - bollywoodhelpline.com
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What analysts say about Anavex Life Sciences Corp stockHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - earlytimes.in
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright - MarketBeat
Can Anavex Life Sciences Corp. stock sustain free cash flow growth2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Can Anavex Life Sciences Corp. stock resist market sell offs2025 Valuation Update & Weekly Watchlist for Consistent Profits - DonanımHaber
Rate Cut: Why Anavex Life Sciences Corp stock could be next big winner2025 Trading Volume Trends & Accurate Buy Signal Notifications - moha.gov.vn
Why Anavex Life Sciences Corp. stock could rally in 2025Stock Surge & Risk Controlled Swing Trade Alerts - ulpravda.ru
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's. Read more here. - Seeking Alpha
Anavex Life Sciences Requests European Medicines Agency to Re-evaluate Blarcamesine as Early Alzheimer's Treatment - marketscreener.com
What catalysts could drive Anavex Life Sciences Corp. stock higher2025 Institutional Moves & Technical Pattern Recognition Alerts - Улправда
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - The Manila Times
Anavex Life Sciences requests EMA to re-examine blarcamesine for Alzheimer's - marketscreener.com
EU regulators asked to revisit an experimental pill for early Alzheimer’s - Stock Titan
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Anavex Life Sciences (AVXL): Analyst Ratings Update for December 15, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital - MarketBeat
Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Louisiana First News
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences Updates on Regulatory Review for Blarcamesine in Treating Early Alzheimer's Disease - Quiver Quantitative
Anavex (NASDAQ: AVXL) to seek CHMP re-exam after EU negative view on blarcamesine - Stock Titan
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025) - ts2.tech
How does Anavex Life Sciences Corporation (AVXL) change from a tortoise to a hare? - Setenews
Anavex Life Sciences Reports Q4 2025 Financials and Updates - MSN
Is Anavex Life Sciences Corp. stock a defensive play in 2025Market Risk Analysis & Growth Focused Stock Reports - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - Benzinga
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) - Finviz
Can Anavex Life Sciences Corp. (12X1) stock sustain institutional flowsMarket Risk Summary & Technical Buy Zone Confirmations - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Shareholders to Connect - ACCESS Newswire
Check Out Anavex Life Sciences Corporation (AVXL)’s Trade Data Rather Than the Analysts’ Views - Setenews
D. Boral Capital Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at D. Boral Capital - Defense World
HC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at D. Boral Capital - Defense World
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Anavex (NASDAQ: AVXL) to present blarcamesine Phase IIb/III Alzheimer’s results at CTAD - Stock Titan
Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2025 - MarketScreener
Anavex Life Sciences Corp. Announces Fourth Quarter 2025 Financial Results and Webcast Details - Quiver Quantitative
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - MarketScreener
Anavex Life Sciences (NASDAQ: AVXL) Quarter 2025 Reports $102.6M, Three-Year Runway - Stock Titan
You might want to take a look at Anavex Life Sciences Corporation (AVXL) now - Setenews
Finanzdaten der Anavex Life Sciences Corporation-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):